Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2) - Dataset (ID:20272)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule 1 | Small Molecule 2 | Small Mol 1 Concentration | Small Mol 2 Concentration | Small Mol Conc Unit | Time Point | Time Point Unit | Replicate | Total Number of Cells (Nuclei) | Number of Apoptotic Cells | Relative Viability | Mean Relative Viability | Apoptosis Fraction | Mean Apoptosis Fraction |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 1.000 | uM | 72 | hr | 2 | 1142 | 1078 | 0.0108 | 0.0099 | 0.9440 | 0.9514 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 3.160 | uM | 72 | hr | 1 | 661 | 623 | 0.0064 | 0.0054 | 0.9425 | 0.9547 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 2 | 1231 | 1160 | 0.0101 | 0.0097 | 0.9423 | 0.9430 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 1.000 | uM | 72 | hr | 3 | 688 | 647 | 0.0074 | 0.0092 | 0.9404 | 0.9423 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 3.160 | uM | 72 | hr | 3 | 1041 | 978 | 0.0104 | 0.0089 | 0.9395 | 0.9423 |
COLO 858 | Vemurafenib | PF562271 | 1.000 | 3.160 | uM | 72 | hr | 1 | 595 | 559 | 0.0065 | 0.0058 | 0.9395 | 0.9416 |
COLO 858 | Vemurafenib | Dasatinib | 3.160 | 3.160 | uM | 72 | hr | 3 | 1115 | 1046 | 0.0099 | 0.0097 | 0.9381 | 0.9430 |
COLO 858 | Vemurafenib | PF562271 | 1.000 | 3.160 | uM | 72 | hr | 2 | 561 | 526 | 0.0063 | 0.0058 | 0.9376 | 0.9416 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 3.160 | uM | 72 | hr | 1 | 486 | 455 | 0.0056 | 0.0041 | 0.9362 | 0.9488 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 3.160 | uM | 72 | hr | 1 | 955 | 894 | 0.0101 | 0.0089 | 0.9361 | 0.9423 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 3.160 | uM | 72 | hr | 3 | 850 | 795 | 0.0065 | 0.0047 | 0.9353 | 0.9535 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 1.000 | uM | 72 | hr | 2 | 1272 | 1188 | 0.0139 | 0.0156 | 0.9340 | 0.9257 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 1.000 | uM | 72 | hr | 2 | 832 | 777 | 0.0099 | 0.0092 | 0.9339 | 0.9423 |
COLO 858 | Vemurafenib | PF562271 | 3.160 | 0.316 | uM | 72 | hr | 3 | 833 | 776 | 0.0103 | 0.0125 | 0.9316 | 0.9029 |
COLO 858 | Vemurafenib | Dasatinib | 1.000 | 0.316 | uM | 72 | hr | 3 | 1258 | 1166 | 0.0131 | 0.0153 | 0.9269 | 0.8976 |
COLO 858 | Vemurafenib | Saracatinib | 3.160 | 0.316 | uM | 72 | hr | 2 | 736 | 681 | 0.0093 | 0.0093 | 0.9253 | 0.9244 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 1.000 | uM | 72 | hr | 3 | 954 | 881 | 0.0121 | 0.0156 | 0.9235 | 0.9257 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 1.000 | uM | 72 | hr | 1 | 1553 | 1428 | 0.0207 | 0.0156 | 0.9195 | 0.9257 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 0.316 | uM | 72 | hr | 3 | 958 | 874 | 0.0139 | 0.0166 | 0.9123 | 0.8947 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 0.000 | uM | 72 | hr | 3 | 1810 | 1651 | 0.0189 | 0.0193 | 0.9122 | 0.9069 |
COLO 858 | Vemurafenib | Defactinib | 3.160 | 0.000 | uM | 72 | hr | 1 | 1712 | 1553 | 0.0189 | 0.0193 | 0.9071 | 0.9069 |
COLO 858 | Vemurafenib | PF562271 | 0.316 | 3.160 | uM | 72 | hr | 3 | 471 | 427 | 0.0079 | 0.0109 | 0.9066 | 0.8930 |
COLO 858 | Vemurafenib | Saracatinib | 1.000 | 1.000 | uM | 72 | hr | 1 | 1107 | 1003 | 0.0176 | 0.0199 | 0.9061 | 0.8770 |
COLO 858 | Vemurafenib | JNK-IN-8 | 3.160 | 0.316 | uM | 72 | hr | 2 | 911 | 825 | 0.0143 | 0.0166 | 0.9056 | 0.8947 |
COLO 858 | Vemurafenib | Dasatinib | 1.000 | 0.316 | uM | 72 | hr | 2 | 1187 | 1073 | 0.0163 | 0.0153 | 0.9040 | 0.8976 |